122 related articles for article (PubMed ID: 24025256)
21. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
Park HJ; Bae JS; Kim KM; Moon YJ; Park SH; Ha SH; Hussein UK; Zhang Z; Park HS; Park BH; Moon WS; Kim JR; Jang KY
J Exp Clin Cancer Res; 2018 May; 37(1):107. PubMed ID: 29784019
[TBL] [Abstract][Full Text] [Related]
22. Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs.
Rudolph J; Roberts G; Luger K
Nat Commun; 2021 Feb; 12(1):736. PubMed ID: 33531508
[TBL] [Abstract][Full Text] [Related]
23. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
[TBL] [Abstract][Full Text] [Related]
24. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
25. Olaparib.
Bochum S; Berger S; Martens UM
Recent Results Cancer Res; 2018; 211():217-233. PubMed ID: 30069770
[TBL] [Abstract][Full Text] [Related]
26. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
27. HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells.
Hombach-Klonisch S; Kalantari F; Medapati MR; Natarajan S; Krishnan SN; Kumar-Kanojia A; Thanasupawat T; Begum F; Xu FY; Hatch GM; Los M; Klonisch T
Mol Oncol; 2019 Feb; 13(2):153-170. PubMed ID: 30289618
[TBL] [Abstract][Full Text] [Related]
28. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
29. H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.
Mazzucchelli S; Truffi M; Baccarini F; Beretta M; Sorrentino L; Bellini M; Rizzuto MA; Ottria R; Ravelli A; Ciuffreda P; Prosperi D; Corsi F
Sci Rep; 2017 Aug; 7(1):7505. PubMed ID: 28790402
[TBL] [Abstract][Full Text] [Related]
30. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
31. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
Norris RE; Adamson PC; Nguyen VT; Fox E
Pediatr Blood Cancer; 2014 Jan; 61(1):145-50. PubMed ID: 24038812
[TBL] [Abstract][Full Text] [Related]
32. PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms.
Matthews Hew T; Zuberi L
J Investig Med High Impact Case Rep; 2019; 7():2324709619864989. PubMed ID: 31375040
[TBL] [Abstract][Full Text] [Related]
33. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
[TBL] [Abstract][Full Text] [Related]
34. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Plummer R
Breast Cancer Res; 2011 Aug; 13(4):218. PubMed ID: 21884642
[TBL] [Abstract][Full Text] [Related]
35. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
Le D; Gelmon KA
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):833-839. PubMed ID: 30118334
[TBL] [Abstract][Full Text] [Related]
36. Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
Yuan Z; Chen S; Sun Q; Wang N; Li D; Miao S; Gao C; Chen Y; Tan C; Jiang Y
Bioorg Med Chem; 2017 Aug; 25(15):4100-4109. PubMed ID: 28601509
[TBL] [Abstract][Full Text] [Related]
37. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
38. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
[TBL] [Abstract][Full Text] [Related]
39. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
[TBL] [Abstract][Full Text] [Related]
40. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
